Prothena Corporation’s Post

International Day of Mastocytosis and Mast Cell Diseases raises awareness about these rare disorders affecting mast cells. It emphasizes the importance of early diagnosis, research, and support for patients. This day promotes understanding and education to improve quality of life and treatment options for those living with these conditions. #MastocytosisAwareness, #MastCellDiseases, #EarlyDiagnosis, #SupportPatients, #RareDiseases, #MedicalResearch, #ImproveQualityOfLife, #PatientEducation

❗This week is #PKDAwarenessWeek. Find out about autosomal recessive polycystic kidney disease (ADPKD). Our webpage covers symptoms, diagnosis, treatment and sources of further information and support: https://lnkd.in/diQvx65q ADPKD facts: 👉 It affects around 1 in 20,000 people in the UK 👉 It is a rare, severe, genetic condition that causes cysts (balloons of fluid) to develop in the kidneys and liver 👉 ADPKD is a genetic condition 👉 Most people with ARPKD develop kidney and/or liver problems during childhood 👉 There are currently no treatments that can cure or slow the progression of ARPKD. Treatment therefore aims to manage the symptoms and should be led by a specialist team with expertise in ARPKD 📞 Our direct patient services are free of charge and provide support to thousands of people with kidney disease and their families every year. Click here to find out more: https://lnkd.in/eyxR9J3w

👋Did you know that screening for colon health should ideally commence at age 50? However, if there's a family history of colorectal cancer or other bowel diseases, it's recommended to start screening at age 40. Your proactive approach to health matters, and discussing the best screening options with your family physician is a crucial step towards early detection and prevention. 🩺 Considering a virtual colonoscopy? Consult with your trusted family physician to determine if it's the right choice for you. Remember, early detection saves lives. If your doctor advises, you can conveniently request your examination through our secure online appointment request system: https://lnkd.in/d2kWzvP3

CAR-T therapy continues to make headlines as it is studied across autoimmune diseases, including myositis. In the early stages of study in myositis, it is showing promising potential in fighting hard-to-treat cases. Read our update from Cure JM Executive Director Jim Minow on what we know currently about CAR-T in myositis and its prospects for the future https://lnkd.in/e8VziD_t

Sickle Cell Disease affects an estimated 70,000 to 100,000 Americans a year, and 11% of patients diagnosed will suffer a stroke before the age of 20. Dr. Manu Platt investigates the underlying mechanisms of vascular permeability in response to sickle cell induced inflammation using the Maestro Z platform in this insightful Coffee Break Webinar 🔗 https://bit.ly/3wZwi84   Watch the 13 minute on-demand case study to discover how: ➡️ Endothelial cells from different vascular beds respond differently to pro- and anti-inflammatory cytokines, as recorded on the Maestro Z platform. ➡️Monocyte-induced endothelial permeability is distinct from cytokine-induced permeability, and there may be patient-specific differences from people living with sickle cell anemia. ➡️The Maestro Z system provides an effective platform for monitoring changes to cell barrier permeability, label-free and in real time.   #SickleCellDisease #TEER #MaestroZ #Impedance

Today is World Sickle Cell Day! This day is dedicated to raising awareness about sickle cell disease. Sickle Cell disease is a genetic blood disorder characterized by the presence of abnormal haemoglobin in the red blood cells🩸and this affects millions worldwide. Sickle cell disease can cause severe pain, anemia, infections, and other serious health issues. 🩸🩸Early detection and treatment are crucial in managing sickle cell disease. We can help improve the quality of life for those affected and support efforts towards better treatment options and ultimately, a cure. #WorldSickleCellDay #SickleCellAwareness

Fully automatic AI-based analysis of mucus plugs provides objective evidence on disease progression and drug efficacy in muco-obstructive diseases. Greater precision and sensitivity in quantification and localization of mucus plugs forms a strong basis for targeted therapies and personalized treatment approaches tailored to individual patients. In combination with the bronchus-artery analysis, it provides a comprehensive assessment of mucus impaction. Learn more about understanding mucus dynamics: https://lnkd.in/eB2-xHdS

Watch this animated video article presenting the results from the phase III ELATIVE® clinical trial, which investigates elafibranor, in patients who have an inadequate response to ursodeoxycholic acid (UDCA). Learn how elafibranor could offer a new approach in treating this rare, chronic liver disease. Watch now: https://hubs.ly/Q02SmJlq0 #PBC #LiverDisease #ELATIVETrial

Sickle Cell Awareness Month is recognized in September, which aims to highlight the challenges faced by individuals living with this condition and promote research and support. Sickle Cell Disease affects hemoglobin in red blood cells, causing them to take on a sickle (crescent) shape, which can block blood flow. Symptoms include episodes of pain (crises), fatigue, anemia, and organ damage. Early diagnosis through newborn screening and proper medical care can improve quality of life. Bone marrow transplants are currently the only cure, though they are not an option for all patients. #TogetherWeFindAWay #PatriotHomeCare #CareRingHealth #SickleCellAwareness #SickleCellMatters #SickleCellWarrior #SickleCellDisease #SickleCellMonth #BreakTheSickleCycle #FightSickleCell #HopeForSickleCell #CureSickleCell #SickleCellSupport #SickleCellStrong #KnowYourSickleStatus

Stage III heterogeneity NSCLC unresectable. Applicability of the Pacific Trial in relation to clinical, disease, patient and prognosis heterogeneity of the stage III